Ro vs Brello: Subscription Model, Medications, and Cost

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies, weight management, and the genetics behind every metabolic decision. Browse all Peptides & GLP-1 education.

This is independent editorial analysis. PlexusDx has no commercial relationship with Ro or Brello, includes no affiliate links, and was not compensated to publish it.

Ro versus Brello is a scale-versus-specialization comparison. Ro is a large, well-known subscription telehealth company; Brello is a smaller, GLP-1-focused compounded program. This fair-balance piece, current to April 2026, looks at what breadth and focus each bring, without pretending one owns the science.

Ro and Brello: scale versus specialization

Ro's advantage is infrastructure and reach across many conditions; Brello's is a narrower focus on GLP-1 care. Scale can mean smoother logistics and support; specialization can mean a tighter offering. Neither trait changes the molecule dispensed, which is why the comparison starts with model, not marketing.

The Ro subscription model

Ro (Roman Health, known as Ro) operates as subscription telehealth. A provider evaluates the patient online, and eligible prescriptions are fulfilled as branded FDA-approved GLP-1 products or compounded semaglutide or tirzepatide through a licensed compounding pharmacy. See its official website for current program details.

The Brello program model

Brello (Brello Health) runs telehealth paired with a compounding pharmacy, with structure, options, and pricing that vary over time. Consult Brello's own site for current details when you read this. Its intake-review-prescribe-ship flow mirrors the broader category, just at a smaller, more focused scale.

Pricing and what's bundled

GLP-1 telehealth pricing spanned roughly $200 to $700 or more per month across the market in April 2026, including program fees, medication, and compounded dispensing where it applies. A larger brand may bundle support differently than a boutique one, and subscription length changes the effective figure. Verify each brand's current pricing on its own page before enrolling.

The evidence is compound-level

Reach does not rewrite pharmacology. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual agonist tirzepatide act identically on appetite and satiety, and the trial record — STEP (NEJM, 2021), SURMOUNT (NEJM, 2022), and SURMOUNT-OSA (NEJM, 2024) — attaches to the molecule, not to Ro or Brello.

What scale does and doesn't buy

Ro's size can translate into smoother logistics, established support channels, and a familiar interface, which some patients value highly. What scale does not buy is a better molecule or a guarantee of individualized care. A focused program like Brello may feel more tailored. Judge each on oversight and terms rather than on brand familiarity alone. If reliable logistics and a polished interface reduce friction enough to keep you consistent, that value is real; just separate it from any implied claim about the medication itself; scale earns trust through consistency, yet a smaller, focused program can deliver that same consistency when it is run carefully.

The genetic dimension both leave out

Whether large or boutique, neither program measures your metabolic baseline. MC4R, central to satiety and energy balance, joins FTO, GLP1R, and TCF7L2 as pathway-level markers of the terrain a clinician prescribes into. They describe biology, not drug response. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights. PlexusDx also offers the compounds through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — and the test does not predict response to any specific medication.

Independence note: PlexusDx is not affiliated with Ro or Brello; this is education, not endorsement.

More reading: GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1, and GLP 1 What Is.

Editorial disclaimer: This comparison is educational. PlexusDx has no tie to Ro or Brello but sells semaglutide and tirzepatide through its own protocols, so read this as a disclosed viewpoint. The Precision Peptide Genetic Test maps gene-pathway influences and does not predict medication response. Consult a qualified provider before starting any protocol.

Consider a genetics-first alternative: view the PlexusDx Weight Management Protocols, or start with the Precision Peptide Genetic Test.

Frequently Asked Questions

Is a large brand like Ro better than a focused one like Brello?

Bigger is not automatically better. Ro brings scale and broad infrastructure; Brello brings a narrower GLP-1 focus. What matters clinically is licensed oversight, a legitimate pharmacy pathway, and transparent terms. Compare those specifics on each brand's own site rather than judging by size alone.

Do Ro and Brello prescribe the same GLP-1 medications?

Both can prescribe GLP-1 receptor agonists such as semaglutide and the dual agonist tirzepatide, dispensed as branded products or compounded preparations depending on eligibility and availability. The platform does not change the drug's action. Confirm the current menu with each brand before enrolling.

Where does PlexusDx fit against a brand like Ro?

PlexusDx sells the same compounds through its Weight Management Protocols and adds the Precision Peptide Genetic Test for upstream context in genes like MC4R. That genetic layer is the differentiator, though it never predicts your response to a specific medication.

Continue learning at the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.